Nightmare disorder. Nightmares
Conditions
Interventions
This study is designed crossover so the following will be done: 4 weeks tamsulosin or placebo 0.4mg capsule every night
2 weeks wash out (neither tamsulosin nor placebo) then 4 weeks placebo or tamsulosin 0.4mg capsule every night. Patients are instructed to take the drug at least half an hour after dinner with a glass
Treatment - Drugs
Sponsors
Islamic azad university of pharmaceutical sciense
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. Nightmare disorder Patients who are interested in treatment and earn necessary score on disturbing dreams and nightmares severity index (DDNSI) questionnaire; 2. No concomitant disease that limit the use of tamsulosin; 3. Quality of life and sleep impairment make drug therapy beneficial; 4. No concomitant drug therapy which have life threatening interactions with tamsulosin Exclusion criteria: 1. Patients who have a low blood pressure occurrence serious side effect; 2. Patients who are not interested for treatment; 3. Patients who have sensitivity to sulfa drugs and tamsulosin or ingredients; 4. Occurrence of serious side effect like severe orthostatic hypotension; 5. Patients with cardiovascolar disease.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction or totally disappearing disturbing dreams and nightmares. Timepoint: Weeks: 0, 4, 6 and 10. Method of measurement: Disturbing dreams and nightmares severity index questionnaire and interviewing about sleep improvement. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reported side effectd-hypotension. Timepoint: Weeks: 0, 4, 6 and 10. Method of measurement: Blood pressure monitoring. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed